Orexigen Therapeutics (OREX) Reports Q1 Loss of $4.67/Share

Orexigen Therapeutics (NASDAQ: OREX) reported Q1 EPS of ($4.67), versus ($1.54) reported last year. Revenue for the quarter came in at $19.1 million versus the consensus estimate of $20 million.

For earnings history and earnings-related data on Orexigen Therapeutics (OREX) click here.

You May Also Be Interested In

• Fabrinet (FN) Tops Q4 EPS by 29c, Beats on Revenue; Offers Guidance
• Is Treasury selloff a major issue for stock market bulls?
• Four Tree Island Advisory calls DoubleDown $11.25 offer too low